Literature DB >> 11809733

Depletion of Lyn kinase from the BCR complex and inhibition of B cell activation by excess CD21 ligation.

Leena Chakravarty1, Mark D Zabel, Janis J Weis, John H Weis.   

Abstract

The human and murine CD21 gene products have been functionally linked to B cell activation by the co-ligation of the BCR and the CD21/CD19/CD81 complexes. Binding of low levels of antigen complexed to the complement ligand(s) for CD21 enhances B cell activation compared to the stimulation caused by antigen alone. Mice lacking functional CD21 predispose to autoimmune responses suggesting that this receptor may also play a negative role: thus in the presence of excess complement-bearing immune complexes, B cell antigen-specific activation may be inhibited. This possibility was investigated using intracellular calcium elicitation analyses to follow BCR-mediated activation. Ligation of the BCR and limiting quantities of the CD21 receptor demonstrated the expected enhanced cellular response compared to BCR ligation alone: CD21 ligation alone demonstrated no alteration in calcium flux. However, co-ligation of the BCR with excess CD21 binding resulted in the elimination of the calcium response, suggesting that CD21 ligation was down-modulating the BCR response. Immunoprecipitation of kinases associated with the BCR and CD21/CD19/CD81 complexes demonstrated that Lyn is preferentially depleted from the BCR complex following excess binding of CD21. Localization of other kinases integral for B cell activation is not altered. These data suggest that excess CD21 ligand binding can negatively impact B cell activation by sequestering Lyn kinase away from the BCR complex.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809733     DOI: 10.1093/intimm/14.2.139

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

1.  CD23+ CD21(high) CD1d(high) B cells in inflamed lymph nodes are a locally differentiated population with increased antigen capture and activation potential.

Authors:  Safiehkhatoon Moshkani; Igor I Kuzin; Funmilola Adewale; Johan Jansson; Iñaki Sanz; Edward M Schwarz; Andrea Bottaro
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

2.  Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3.

Authors:  Jason Twohig; Liudmila Kulik; Catherine Haluszczak; Jason Reuter; Andreas Rossbach; Melanie Bull; V Michael Holers; Kevin J Marchbank
Journal:  Mol Immunol       Date:  2007-03-26       Impact factor: 4.407

3.  Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.

Authors:  Kelly R Young; Benjamin E Teal; Yvonne Brooks; Thomas D Green; Joseph F Bower; Ted M Ross
Journal:  AIDS Res Hum Retroviruses       Date:  2004-11       Impact factor: 2.205

4.  CD21 signaling via C3 regulates Purkinje cell protein 4 expression.

Authors:  Amanda C Jacobson; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-02-07       Impact factor: 4.407

5.  CD21/35 promotes protective immunity to Streptococcus pneumoniae through a complement-independent but CD19-dependent pathway that regulates PD-1 expression.

Authors:  Karen M Haas; Jonathan C Poe; Thomas F Tedder
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

Review 6.  Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus.

Authors:  Brendan M Giles; Susan A Boackle
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

7.  Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.

Authors:  Jian Zhao; Brendan M Giles; Rhonda L Taylor; Gabriel A Yette; Kara M Lough; Han Leng Ng; Lawrence J Abraham; Hui Wu; Jennifer A Kelly; Stuart B Glenn; Adam J Adler; Adrienne H Williams; Mary E Comeau; Julie T Ziegler; Miranda Marion; Marta E Alarcón-Riquelme; Graciela S Alarcón; Juan-Manuel Anaya; Sang-Cheol Bae; Dam Kim; Hye-Soon Lee; Lindsey A Criswell; Barry I Freedman; Gary S Gilkeson; Joel M Guthridge; Chaim O Jacob; Judith A James; Diane L Kamen; Joan T Merrill; Kathy Moser Sivils; Timothy B Niewold; Michelle A Petri; Rosalind Ramsey-Goldman; John D Reveille; R Hal Scofield; Anne M Stevens; Luis M Vilá; Timothy J Vyse; Kenneth M Kaufman; John B Harley; Carl D Langefeld; Patrick M Gaffney; Elizabeth E Brown; Jeffrey C Edberg; Robert P Kimberly; Daniela Ulgiati; Betty P Tsao; Susan A Boackle
Journal:  Ann Rheum Dis       Date:  2014-09-01       Impact factor: 19.103

8.  A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.

Authors:  Eva-Maria Nichols; Rachel Jones; Rachael Watson; Chris J Pepper; Chris Fegan; Kevin J Marchbank
Journal:  Oncotarget       Date:  2015-10-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.